on-resectable colorectal liver metastases of KRAS mutant type treated with oxaliplatin, fluorouracil and l-leucovorin plus bevacizumab induction toward liver R0 resection trial - NEXTO-mt

Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2012年12月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Prior local therapy for liver metastases (2) Severe comorbidity (3) A past history of drug allergy (needs continuation therapy) (4) A past history of Interstitial lung disease (5) A past history of hemoptysis (6) Patients who has not recovered from previous cancer treatment to less than Grade 1 toxicity (7) Fully recovered from surgical treatment within 4 weeks before registration (8) Received widespread radiation therapy within 6 weeks before registration (9) Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval (10) Severe infectious disease (11) Pleural effusion, ascites fluid and the pericardial fluid needing treatment (12) Watery diarrhea (watery colostomy output without trouble during patient's daily living is allowed) (13) Chronic systemic treatment of corticosteroid (14) Bleeding tendency, coagulation disorder, abnormality of coagulation factor, or administered anticoagulant (15) HBsAg positive, HCV-Ab positive or HIV positive (16) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (17) Psychological disorder (18) Considered not appropriate for surgery (19) Patients who are judged inappropriate for the entry into the study by the investigator

发起方

Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine